Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO

Teng, N.Dalby, M. J.Kiu, R.Robinson, T.Cortes, M. GionBermejo De las Heras, B.Perez Garcia, J. M.Calvo-Martinez, L.Prat, A.Marquez Vazquez, R.Ruiz Borrego, M.de la Cruz, S.Llombart Cussac, A.Curigliano, G.Schmid, P.Mancino, M.Hall, L.Robinson, S.Cortes, J.Malfettone, A.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21897enGut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIOconference outputopen access10.1016/j.annonc.2022.03.0291569-8041http://www.annalsofoncology.org/article/S0923753422004082/pdf792494100017